In the year 2000, psychiatry experienced one of the most important breakthroughs in decades: researchers showed that ketamine, a widely used anesthetic, could produce a powerful antidepressant effect within hours. For patients suffering from severe depression, this was something radically new. Traditional antidepressants take weeks or months to work, and many patients never respond at all. Ketamine was capable of relieving depressive symptoms in the majority of these patients rapidly, even when they did not respond to several conventional antidepressants.
May is Mental Health Awareness Month — a time to open up conversations we often keep quiet. If you or someone you love has been struggling with depression, anxiety, or PTSD, you already know how hard that silence can feel. You may have tried medications, therapy, or both, and still found yourself searching for something that actually works.
Ketamine therapy for mental health is giving new hope to people who haven’t found relief through traditional treatments. At Charleston Ketamine Center, we believe everyone deserves to understand their options — so let’s talk about what ketamine treatment is, who it may help, and what the experience actually looks like.
What Is Mental Health Awareness Month?
Every May, Mental Health Awareness Month encourages people across the country to break the stigma around mental health conditions, seek support, and share their stories. According to the National Alliance on Mental Illness (NAMI), 1 in 5 adults in the U.S. experiences a mental health condition each year — yet many people go without treatment.
Awareness month is a reminder that mental health conditions like depression, anxiety, and post-traumatic stress disorder (PTSD) are medical conditions — not personal failures. And like any medical condition, they deserve evidence-based treatment options.
What Is Ketamine Therapy?
Ketamine is a medication that has been used safely in medical settings for decades, primarily as an anesthetic. In recent years, researchers and clinicians have found that low-dose ketamine infusions may significantly reduce symptoms of certain mental health conditions — sometimes within hours or days, rather than the weeks it typically takes for traditional antidepressants to take effect.
Ketamine works differently from most mental health medications. Rather than targeting serotonin or dopamine (as most antidepressants do), ketamine acts on a receptor in the brain called NMDA (N-methyl-D-aspartate). This process may help restore connections between brain cells that have been weakened by long-term stress and depression.
At Charleston Ketamine Center, ketamine is administered by a medical doctor in a safe, monitored clinical setting — never at home, and never without oversight.
Who Might Benefit From Ketamine Therapy for Mental Health?
Ketamine therapy may be an option for people living with:
Research suggests ketamine may be particularly helpful for people who have tried other treatments without success. If you’ve felt like you’ve run out of options, it may be worth having a conversation with a provider about whether ketamine is appropriate for you.
When to Talk to a Provider
If any of these sound familiar, it may be worth reaching out for a consultation:
You don’t need to have everything figured out before making a call. A consultation is simply a chance to ask questions and learn more.
Taking the Next Step This Mental Health Awareness Month
Mental Health Awareness Month is about more than raising awareness — it’s about taking action. If you or someone you care about has been struggling, this May is a meaningful time to explore what options might help.
Ketamine therapy for mental health is not a last resort — it’s a legitimate, medically supervised treatment that may offer relief when other approaches haven’t. At Charleston Ketamine Center, our physician is here to have an honest conversation about whether it’s right for you.
Call us at (843) 480-2273 to take the next step — at whatever pace feels right for you.
This article is for educational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider to discuss your individual situation.
This article examines the evolving understanding of depression and the mechanisms behind ketamine’s antidepressant effects. It discusses the shift away from the traditional “chemical imbalance” theory toward a broader focus on neural connectivity, synaptic function, and brain plasticity. The authors explain how ketamine may rapidly restore communication pathways within the brain, offering a different therapeutic approach than conventional antidepressants. The paper also explores emerging research into multiscale plasticity and how these findings may influence the future of depression treatment and neuroscience.
A recent study published on PubMed highlights promising findings in the treatment of depression using intranasal ketamine. Researchers found that racemic ketamine is non-inferior to esketamine, meaning it delivers comparable improvements in depressive symptoms while potentially offering a more cost-effective and accessible option for patients. This is especially important as demand grows for fast-acting alternatives to traditional antidepressants.
At Charleston Ketamine Center, these findings reinforce the value of ketamine-based therapies in real-world clinical care. Intranasal treatment options provide a convenient, minimally invasive approach while maintaining strong therapeutic outcomes. As research continues to evolve, ketamine therapy remains a powerful tool in helping patients achieve meaningful relief from depression and improve overall quality of life.
Telehealth ketamine therapy provider Mindbloom is facing a wrongful-death lawsuit after a 27-year-old male patient died from ketamine toxicity in October 2023, allegedly while under Mindbloom’s at-home treatment program. The lawsuit contends that the company failed to properly screen the patient—who had a documented history of substance-use disorder and hypertension—and did not follow through with required follow-up monitoring once he missed mandated check-ins. The patient’s family argues that, despite Mindbloom’s public claim that none of its ~60,000 patients had ever overdosed, this case marks a tragic exception. Mindbloom, while expressing sympathy for the death, denies negligence and asserts its care protocols are supported by peer-reviewed research and numerous prior treatments.
For over 50 years, ketamine has been known as a safe anesthetic, and at lower doses, an effective treatment for depression. Emerging research suggests it may also enhance cognition and neuroplasticity, offering hope for patients with neurological disorders such as Parkinson’s, multiple sclerosis, and brain injury. Animal studies show ketamine promotes synaptogenesis and improved memory, while human research remains limited. Combining ketamine with cognitive rehabilitation may enable not only symptom relief but also potential restoration of lost cognitive function.
A retrospective study of 153 patients with severe treatment-resistant depression found that twice-weekly IV ketamine over 4–5 weeks led to faster and greater symptom reduction than intranasal esketamine, with overall tolerability similar. IV ketamine produced significant improvement after the first session, while IN esketamine’s effects emerged after the second. Final depression scores decreased 49.8% with IV ketamine versus 39.5% with IN esketamine. Dropout rates and side effects were comparable, highlighting both as valuable neuropsychiatric tools.
A four-year Cleveland Clinic study of 1,034 patients found that low-dose ketamine infusions significantly improved pain, sleep, and daily function for 20%–46% of people with chronic pain, with benefits lasting up to six months. Nearly half reported reduced pain-related anxiety, and 80% returned for repeat treatments. The therapy was safe, with rare side effects. Researchers say ketamine offers a promising, non-opioid option for chronic pain management and may pave the way for future FDA approval.
A Cleveland Clinic study found that low-dose IV ketamine infusions are safe and effective for chronic pain management. Among more than 1,000 patients, 20%–46% saw lasting improvements in pain, physical function, and sleep for at least six months, with minimal side effects. Nearly half reported reduced pain-related anxiety, and 80% returned for additional treatments. Researchers say ketamine offers a promising, non-opioid option for patients with chronic pain who have exhausted other therapies.
Ketamine has emerged as a promising treatment for suicidal ideation (SI) in patients with major depressive disorder (MDD), showing rapid and sustained reductions in suicidality. Studies from 2020–2025 found IV ketamine and esketamine significantly decreased SI for days to weeks, with early responders showing lower suicide risk at three months. While its mechanisms—such as reduced lateral habenula activity—are still being studied, ketamine must be used alongside therapy, monitoring, and comprehensive psychiatric care to ensure safety and effectiveness.
